Overactive bladder in an integrated delivery system: a longitudinal cohort study
Abstract Background Overactive bladder (OAB) is common and morbid. Medication and diagnosis claims may be specific, but lack sensitivity to identify patients with overactive bladder. We used an “electronic health record (EHR) phenotype” to identify cases and describe treatment choices and anticholin...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-05-01
|
| Series: | BMC Health Services Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12913-020-05315-1 |
| _version_ | 1818906766143913984 |
|---|---|
| author | Jeffrey A. Linder Joel S. Weissman Harry Reyes Nieva Stuart Lipsitz R. Sterling Haring Julie DeAngelis Rita M. Kristy Kevin R. Loughlin |
| author_facet | Jeffrey A. Linder Joel S. Weissman Harry Reyes Nieva Stuart Lipsitz R. Sterling Haring Julie DeAngelis Rita M. Kristy Kevin R. Loughlin |
| author_sort | Jeffrey A. Linder |
| collection | DOAJ |
| description | Abstract Background Overactive bladder (OAB) is common and morbid. Medication and diagnosis claims may be specific, but lack sensitivity to identify patients with overactive bladder. We used an “electronic health record (EHR) phenotype” to identify cases and describe treatment choices and anticholinergic burden for OAB. Methods We conducted a retrospective cohort study in a large, integrated health delivery system between July 2011 and June 2012 (2-year follow-up). We examined care from primary care and specialty clinics, medication and procedure use, and anticholinergic burden for each patient. Results There were 7362 patients with an EHR OAB phenotype; 50% of patients were > 65 years old, 74% were female, and 83% were white. The distribution of care included primary care physician (PCP)/specialty co-management (25% of patients); PCP care only (18%); urology only (13%); or some other combination of specialty care (33%). Only 40% of patients were prescribed at least 1 OAB medication during the study. The mean duration of prescribed medication was 1.5 months (95% confidence interval [CI], 1.4 to 1.6 months; range, < 1 month to 24 months). Independent predictors of receipt of an OAB medication included increasing age (odds ratio [OR], 1.4 for every 10 years; 95% CI, 1.4 to 1.5), women (OR, 1.6 compared with men; 95% CI, 1.4 to 1.8), diabetes (OR, 1.3; 95% CI, 1.1 to 1.5), and certain sources of care compared with PCP-only care: PCP/specialty co-management (OR, 1.8; 95% CI, 1.5 to 2.0), urology (OR, 2.2; 95% CI, 1.8 to 2.6), and multiple specialists (OR, 1.4; 95% CI, 1.2 to 1.8). Very few patients received other treatments: biofeedback (< 1%), onabotulinumtoxinA (2%), or sacral nerve stimulation (1%). Patients who received OAB medications had significantly higher anticholinergic burden than patients who did not (anticholinergic total standardized daily dose, 125 versus 46; P < .001). Conclusions Although OAB is common and morbid, in a longitudinal study using an EHR OAB phenotype 40% of patients were treated with OAB medication and only briefly. |
| first_indexed | 2024-12-19T21:44:26Z |
| format | Article |
| id | doaj.art-fcd8af5e539047ee9bb35556877cfdde |
| institution | Directory Open Access Journal |
| issn | 1472-6963 |
| language | English |
| last_indexed | 2024-12-19T21:44:26Z |
| publishDate | 2020-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Health Services Research |
| spelling | doaj.art-fcd8af5e539047ee9bb35556877cfdde2022-12-21T20:04:34ZengBMCBMC Health Services Research1472-69632020-05-012011910.1186/s12913-020-05315-1Overactive bladder in an integrated delivery system: a longitudinal cohort studyJeffrey A. Linder0Joel S. Weissman1Harry Reyes Nieva2Stuart Lipsitz3R. Sterling Haring4Julie DeAngelis5Rita M. Kristy6Kevin R. Loughlin7Division of General Internal Medicine and Geriatrics, Northwestern University Feinberg School of MedicineCenter for Surgery and Public Health, Brigham and Women’s Hospital, Harvard Medical SchoolDivision of General Internal Medicine and Primary Care, Brigham and Women’s Hospital, Harvard Medical SchoolCenter for Surgery and Public Health, Brigham and Women’s Hospital, Harvard Medical SchoolDepartment of Physical Medicine and Rehabilitation, Vanderbilt University Medical CenterAstellas Pharma Global DevelopmentAstellas Pharma Global DevelopmentDivision of Urology, Brigham and Women’s Hospital, Harvard Medical SchoolAbstract Background Overactive bladder (OAB) is common and morbid. Medication and diagnosis claims may be specific, but lack sensitivity to identify patients with overactive bladder. We used an “electronic health record (EHR) phenotype” to identify cases and describe treatment choices and anticholinergic burden for OAB. Methods We conducted a retrospective cohort study in a large, integrated health delivery system between July 2011 and June 2012 (2-year follow-up). We examined care from primary care and specialty clinics, medication and procedure use, and anticholinergic burden for each patient. Results There were 7362 patients with an EHR OAB phenotype; 50% of patients were > 65 years old, 74% were female, and 83% were white. The distribution of care included primary care physician (PCP)/specialty co-management (25% of patients); PCP care only (18%); urology only (13%); or some other combination of specialty care (33%). Only 40% of patients were prescribed at least 1 OAB medication during the study. The mean duration of prescribed medication was 1.5 months (95% confidence interval [CI], 1.4 to 1.6 months; range, < 1 month to 24 months). Independent predictors of receipt of an OAB medication included increasing age (odds ratio [OR], 1.4 for every 10 years; 95% CI, 1.4 to 1.5), women (OR, 1.6 compared with men; 95% CI, 1.4 to 1.8), diabetes (OR, 1.3; 95% CI, 1.1 to 1.5), and certain sources of care compared with PCP-only care: PCP/specialty co-management (OR, 1.8; 95% CI, 1.5 to 2.0), urology (OR, 2.2; 95% CI, 1.8 to 2.6), and multiple specialists (OR, 1.4; 95% CI, 1.2 to 1.8). Very few patients received other treatments: biofeedback (< 1%), onabotulinumtoxinA (2%), or sacral nerve stimulation (1%). Patients who received OAB medications had significantly higher anticholinergic burden than patients who did not (anticholinergic total standardized daily dose, 125 versus 46; P < .001). Conclusions Although OAB is common and morbid, in a longitudinal study using an EHR OAB phenotype 40% of patients were treated with OAB medication and only briefly.http://link.springer.com/article/10.1186/s12913-020-05315-1AntimuscarinicsAnticholinergic burdenElectronic health recordsIntegrated delivery systemMedication and procedure useOveractive bladder |
| spellingShingle | Jeffrey A. Linder Joel S. Weissman Harry Reyes Nieva Stuart Lipsitz R. Sterling Haring Julie DeAngelis Rita M. Kristy Kevin R. Loughlin Overactive bladder in an integrated delivery system: a longitudinal cohort study BMC Health Services Research Antimuscarinics Anticholinergic burden Electronic health records Integrated delivery system Medication and procedure use Overactive bladder |
| title | Overactive bladder in an integrated delivery system: a longitudinal cohort study |
| title_full | Overactive bladder in an integrated delivery system: a longitudinal cohort study |
| title_fullStr | Overactive bladder in an integrated delivery system: a longitudinal cohort study |
| title_full_unstemmed | Overactive bladder in an integrated delivery system: a longitudinal cohort study |
| title_short | Overactive bladder in an integrated delivery system: a longitudinal cohort study |
| title_sort | overactive bladder in an integrated delivery system a longitudinal cohort study |
| topic | Antimuscarinics Anticholinergic burden Electronic health records Integrated delivery system Medication and procedure use Overactive bladder |
| url | http://link.springer.com/article/10.1186/s12913-020-05315-1 |
| work_keys_str_mv | AT jeffreyalinder overactivebladderinanintegrateddeliverysystemalongitudinalcohortstudy AT joelsweissman overactivebladderinanintegrateddeliverysystemalongitudinalcohortstudy AT harryreyesnieva overactivebladderinanintegrateddeliverysystemalongitudinalcohortstudy AT stuartlipsitz overactivebladderinanintegrateddeliverysystemalongitudinalcohortstudy AT rsterlingharing overactivebladderinanintegrateddeliverysystemalongitudinalcohortstudy AT juliedeangelis overactivebladderinanintegrateddeliverysystemalongitudinalcohortstudy AT ritamkristy overactivebladderinanintegrateddeliverysystemalongitudinalcohortstudy AT kevinrloughlin overactivebladderinanintegrateddeliverysystemalongitudinalcohortstudy |